Outcome of the Board meeting held on 13th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 2.9 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech Limited reported audited consolidated results for the year ended March 31, 2025, showing a sharp swing from profit to loss. Full-year revenue from operations fell about 22% to Rs 13,022.84 lakhs (from Rs 16,622.56 lakhs in FY24). The company posted a loss after tax of Rs 610.75 lakhs compared to a profit of Rs 1,042.25 lakhs last year, with EPS turning negative at Rs (1.35) versus Rs 1.40. Finance costs rose roughly 19% to Rs 1,176.27 lakhs, squeezing margins further. On the balance sheet, short-term borrowings jumped nearly 75% to Rs 7,165.72 lakhs, while cash on hand fell to just Rs 28.82 lakhs. Operating cash flow remained negative at Rs (674.18) lakhs. Statutory auditor Venkatesh & Co. issued an unmodified opinion, though financials of three subsidiaries and two step-down subsidiaries were management-certified and not audited.
Full-year results show a significant deterioration—declining revenue, negative profitability, rising debt, and weak cash generation. The surge in short-term borrowings against very low cash heightens liquidity risk. Shareholders should monitor debt servicing capacity and subsidiary-level performance closely.